Escient Pharmaceuticals Announces Positive Results from Phase 1 Study of EP262, a First-in-Class Oral MRGPRX2 Antagonist for Mast Cell Mediated Disorders

– EP262 was safe and well-tolerated at all doses tested, at exposures several fold above doses required for efficacy in preclinical disease models – Pharmacokinetic (PK) profile supports once-daily oral dosing – Clinical proof-of-concept studies in chronic inducible urticaria, chronic spontaneous urticaria and atopic dermatitis to start in second half of 2023 SAN DIEGO, Calif., […] The post Escient Pharmaceuticals Announces Positive Results from Phase 1 Study of EP262, a First-in-Class Oral MRGPRX2 Antagonist for Mast Cell Mediated Disorders appeared first on Escient pharmaceuticals .